Abiologics Strengthens Leadership Team with Appointment of Maria-Chiara Magnone as Chief Scientific Officer
September 25 2024 - 7:00AM
Abiologics, a company reimagining biologics with the creation of a
new class of supranatural and programmable medicines called
Synteins™, today announced the appointment of Maria-Chiara Magnone,
Ph.D., as Chief Scientific Officer. Magnone brings two decades of
experience in all stages of drug development across a wide range of
therapeutic areas.
“Maria-Chiara has the skills, experience and drive to match
Abiologics’ ambitious vision to transcend the limits of biology and
offer a new class of medicines with significant advantages compared
to today’s biologics,” said Avak Kahvejian, Ph.D., Co-Founder and
CEO of Abiologics and General Partner at Flagship Pioneering. “I’m
thrilled to welcome her to the team at this critical inflection
point for the company as we leverage our platform to create a
strong pipeline of supranatural biologics.”
Magnone joins Abiologics from Johnson & Johnson (J&J),
where she was initially Vice President, Kidney Disease Research and
Boston Site Head, and more recently Vice President, Head of
Discovery for the Cardiovascular, Metabolic, Retina and Pulmonary
Hypertension therapeutic area. During her time at J&J, she
led efforts to develop the kidney disease area strategy and
pipeline through internal programs and external asset acquisition,
and played a key role in advancing several programs to clinical
candidate selection. Prior to J&J, she served as Head of
Translational Sciences at AstraZeneca, where she led the
establishment and implementation of the translational strategy
across the cardiovascular, metabolism and renal portfolio. Magnone
began her career in drug discovery and early development and held
positions of increasing responsibility at Roche, Novartis and
Serono in discovery and development in metabolism and
neuroscience.
“The specificity and broad applicability of biologics have
transformed medicine. By going beyond nature’s toolbox, Abiologics
is creating a new class of programmable medicines with
extraordinary properties, with the vision to transcend the
potential of biologics,” said Magnone. “I look forward to working
with the team to apply the company’s unique platform to create a
breadth of new medicines that can redefine what therapeutics can
achieve for patients.”
About AbiologicsAbiologics is pioneering a new
class of supranatural and programmable biologics, called Synteins™.
The Abiologics platform leverages cutting-edge generative
artificial intelligence and high-throughput chemical protein
synthesis to computationally-design Synteins de novo using a broad
set of artificial building blocks, far beyond the 20 naturally
occurring amino acids that form the basis of today’s biologic
medicines. Synteins have powerful, desirable pharmacological
properties, and can be programmed to interact with virtually any
therapeutic target while evading the body’s natural defenses,
offering significant advantages compared to today’s biologics, such
as less frequent dosing, oral delivery and the ability to reach
parts of the body that were previously impossible to access and
treat. Abiologics was founded by Flagship Pioneering in 2021. For
more information, visit us at www.abiologics.com and follow us on
LinkedIn and X/Twitter.
Media Contact: press@abiologics.com